|
|
 | | | | | | | Germany
Indication: For epilepsy: simple partial attacks (focal); complex attacks (psychomotoric); grand mal, especially of focal genesis (sleep grand mal and diffuse grand mal); mixed types of epilepsy; attack-like face pain (trigeminus neuralgia); genuine glossopharingeus neuralgia; diabetic neuropathy; and alcohol withdrawal syndrome (Carbaflux 300 mg only in-hospital treatment). Also indicated for prophylaxis of manic-depressive episodes when lithium therapy has failed or the patient has a contraindication for lithium.
Brand name: Tegretol, Carbaflux 300 mg retard (retard tablet) (Henning Arzneimittel GmbH & Co. KG).
Regulatory status: No further indications expected.
Launch date: 16 November 1998.
| | | |
|
